Literature DB >> 4052934

A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck.

M A Cobleigh, J H Hill, P A Gallagher, L J Kukla, T E Lad, D H Shevrin, E L Applebaum, W P McGuire.   

Abstract

Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m2 at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 evaluable tumors. We conclude that Adriamycin is a highly active drug in SCC H/N when no prior treatment has been administered.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4052934     DOI： 10.1002/1097-0142(19851201)56:11<2573::aid-cncr2820561106>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.

Authors:  Sahar A Saddoughi; Elizabeth Garrett-Mayer; Uzair Chaudhary; Paul E O'Brien; Larry B Afrin; Terry A Day; M Boyd Gillespie; Anand K Sharma; Christina S Wilhoit; Robin Bostick; Can E Senkal; Yusuf A Hannun; Jacek Bielawski; George R Simon; Keisuke Shirai; Besim Ogretmen
Journal:  Clin Cancer Res       Date:  2011-07-26       Impact factor: 12.531

3.  A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.

Authors:  P H De Mulder; P Cappelaere; F Cognetti; J Verweij; J H Schornagel; J B Vermorken; A Kirkpatrick; J L Lefebvre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.